Rundong Keruohua Pharmaceutical Research & Development (Shanghai) Co., Ltd., a joint venture of Chinese and Japanese pharmaceutical R&D companies, was established in Shanghai. The establishment of this company will strengthen cooperation research between the two countries in the field of pharmaceutical R&D.
The development of new drugs is costly, long-term, and high-risk. Because it involves people's health and life safety, the relevant drug laws and regulations in various countries have continued to improve in recent years.
It is understood that CRO (Contract Research Organization), which is currently used in the world, is a scientific institution that ensures the quality of drug research and development to reduce risks and provides professional services related to drug research and development to biopharmaceutical companies.
The joint venture company Rundong Pharmaceutical Research & Development (Shanghai) Co., Ltd. is one of the rapidly growing CRO companies in China in recent years. The company not only conducts clinical research but also conducts various training activities for clinical research institutions GCP with relevant departments; CRONOVA Co., Ltd. is the only CRO company in Japan that has passed all four standard certifications in the industry. It is also one of the best and fastest-growing CRO companies in Japan in recent years.
Guo Yunpei, vice president of the China Pharmaceutical Quality Management Association, who attended the inauguration ceremony, said that in recent years, China's pharmaceutical market has developed rapidly. However, due to fierce market competition, CRO companies have had a mixed situation, and local companies with genuine strict quality standards have become paralyzed. Few. The successful cooperation between Rundong Pharmaceutical Research and Development (Shanghai) Co., Ltd. and Japan's Cronova Inc., not only in terms of market development, quality standards, and resource sharing, but also complements the advantages of the pharmaceutical industry in both China and Japan. The exchanges and developments provide technical support for high-quality pharmaceutical products entering the market as soon as possible.
The development of new drugs is costly, long-term, and high-risk. Because it involves people's health and life safety, the relevant drug laws and regulations in various countries have continued to improve in recent years.
It is understood that CRO (Contract Research Organization), which is currently used in the world, is a scientific institution that ensures the quality of drug research and development to reduce risks and provides professional services related to drug research and development to biopharmaceutical companies.
The joint venture company Rundong Pharmaceutical Research & Development (Shanghai) Co., Ltd. is one of the rapidly growing CRO companies in China in recent years. The company not only conducts clinical research but also conducts various training activities for clinical research institutions GCP with relevant departments; CRONOVA Co., Ltd. is the only CRO company in Japan that has passed all four standard certifications in the industry. It is also one of the best and fastest-growing CRO companies in Japan in recent years.
Guo Yunpei, vice president of the China Pharmaceutical Quality Management Association, who attended the inauguration ceremony, said that in recent years, China's pharmaceutical market has developed rapidly. However, due to fierce market competition, CRO companies have had a mixed situation, and local companies with genuine strict quality standards have become paralyzed. Few. The successful cooperation between Rundong Pharmaceutical Research and Development (Shanghai) Co., Ltd. and Japan's Cronova Inc., not only in terms of market development, quality standards, and resource sharing, but also complements the advantages of the pharmaceutical industry in both China and Japan. The exchanges and developments provide technical support for high-quality pharmaceutical products entering the market as soon as possible.